News

Baheal rebrands to Baheal Pharmaceutical as manufacturing drives 36% of profit

What's the deal? Baheal PharmaceuticalDealroom has a profile for this one. Try Dealroom → (formerly Baheal Medical, Shenzhen: 301015) said its stock ticker and corporate name will change from "Baheal Medical" to "Baheal Pharmaceutical" starting November 12, 2026. The stock code stays the same. The shift follows its 2024 acquisition of a 60.199% stake in Shanghai Baiyang Pharmaceutical Co., Ltd., which pushed the company from drug marketing into research and manufacturing.

Why now? In the 12 months from July 2025 to June 2026, the acquired manufacturing business contributed 36.03% of the company's 2025 audited operating profit, on 13.89% of audited revenue. The company said that threshold meets Shenzhen Stock Exchange ChiNext rules for a name change.

What's the endgame? The firm is repositioning from a "commercialisation platform" to a full-chain group spanning research, production, and sales. Its manufacturing base holds US Food and Drug Administration cGMP certification, and a high-end production site that opened in December 2025 serves as the global hub for the ZAP-X radiosurgery robot.

The rename was approved by the board on October 20, 2026, and by shareholders on November 5, with business registration now complete. The company stressed that its legal entity is unchanged and that existing contracts, debts, and licences remain valid.

What could go wrong? The rebrand lands amid pressure on the core business: revenue fell 7.27% year-on-year in the first three quarters of 2026, while net profit attributable to shareholders dropped 49.71%. A subsidiary is also seeking US$190.2M over a brand-operation contract dispute that has not yet been heard, leaving its impact unclear.

The acquired unit's 2025 net profit excluding non-recurring items reached about US$27.8M, beating its performance commitment. That shows manufacturing is contributing, but it does not confirm the group has completed its transition.

The signal: The move reads as a post-acquisition strategic repositioning rather than a fresh deal or earnings milestone. The real test is whether manufacturing can keep growing fast enough to cushion a weakening legacy business.

Read more: sohu.com

Image credit: Generated with Gemini

More top stories